Cytek Biosciences Form 4: Director Equity Grant on 18 Jun 2025

Rhea-AI Filing Summary

Cytek Biosciences, Inc. (CTKB) – Form 4 insider filing, 20 Jun 2025

Director Deborah J. Neff reported two equity awards granted on 18 Jun 2025 as part of routine board compensation.

• Restricted Stock Units (RSUs): 43,973 units, each convertible into one share of common stock. Vesting: 100 % vests on the earlier of 18 Jun 2026 or the company’s 2026 annual shareholder meeting (if held in June 2026). Until vesting, the units remain contingent and non-transferable.
• Non-qualified Stock Options: 23,809 options with an exercise price of $3.07 per share. Vesting mirrors the RSUs—100 % on the earlier of 18 Jun 2026 or the 2026 annual meeting—and the options expire on 18 Jun 2035, giving a 10-year life after vesting.

Both awards are recorded as “A” (acquired) transactions, increasing the director’s derivative holdings to 43,973 RSUs and 23,809 options. No common-stock sales or purchases were disclosed, and no non-derivative ownership changes were reported.

Because the combined 67,782 potentially issuable shares represent a very small fraction of Cytek’s total shares outstanding, the filing is primarily informational and typical for board-level equity incentives. The grant reinforces alignment between the director and shareholders but does not, on its own, alter the company’s capital structure or financial outlook.

Insights

Corporate Governance Expert

TL;DR – Routine equity grant; aligns director incentives, minimal dilution, neutral impact.

This Form 4 reflects standard annual compensation for an independent director. The single-tranche vesting schedule, coordinated with the 2026 AGM, is typical and promotes retention through the next proxy cycle. The modest size—< 0.1 % of shares outstanding—results in negligible dilution risk. No red flags such as accelerated vesting, below-market exercise pricing, or sales were noted. Governance perspective: neutral.

Portfolio Manager

TL;DR – Immaterial to valuation; signals ongoing board engagement, no trading signal.

The awards total 67.8k shares (derivative form) versus a multi-hundred-million-share float, so valuation metrics, EPS forecasts, and liquidity remain unchanged. Absence of dispositions suggests no bearish sentiment from the director. Given the standard 10-year option term and one-year cliff vest, the event does not influence near-term supply/demand dynamics. Portfolio stance remains driven by fundamentals, not this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEFF DEBORAH J

(Last) (First) (Middle)

C/O CYTEK BIOSCIENCES, INC.

47215 LAKEVIEW BLVD.

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cytek Biosciences, Inc. [ CTKB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/18/2025		A		43,973		(2)	(2)	Common Stock	43,973	$0	43,973	D
Director Stock Option (right to buy)	$3.07	06/18/2025		A		23,809		(3)	06/18/2035	Common Stock	23,809	$0	23,809	D

Explanation of Responses:

1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.

2. 100% of the shares subject to the RSU Award shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).

3. 100% of the shares subject to the option shall vest on the earlier of June 18, 2026 and the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).

	/s/ Valerie Barnett, Attorney-in-Fact	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many RSUs did CTKB director Deborah Neff receive on 18 June 2025?

43,973 restricted stock units were granted, each convertible into one share of Cytek common stock.

What is the exercise price of the stock options granted to the CTKB director?

The options carry an exercise price of $3.07 per share.

When will the RSUs and options vest according to the Form 4 filing?

Both awards vest 100 % on the earlier of 18 Jun 2026 or the 2026 annual meeting (if held in June 2026).

Did the filing report any sale of CTKB shares by the director?

No. All reported transactions were coded “A” (acquisitions); no sales or disposals were disclosed.

What is the expiration date of the director’s new stock options?

The options expire on 18 June 2035, ten years after the grant date.